Table 4.
Adverse events of special interest (EXS, actual treatment cohort)
| Grouping | Conventional systemic N = 182 n (%) |
Secukinumab N = 211 n (%) |
Other biologics N = 213 n (%) |
Nonea N = 125 n (%) |
|---|---|---|---|---|
| Number of subjects with at least one event | 22 (12.1) | 47 (22.3) | 40 (18.8) | 9 (7.2) |
| Hypersensitivity | 2 (1.1) | 9 (4.3) | 11 (5.2) | 2 (1.6) |
| Immune/administration reactions | 0 | 1 (0.5) | 4 (1.9) | 0 |
| Infections | 10 (5.5) | 35 (16.6) | 25 (11.7) | 6 (4.8) |
| Infections (infectious pneumonia) | 0 | 1 (0.5) | 1 (0.5) | 1 (0.8) |
| Infections (fungal) | 0 | 7 (3.3) | 4 (1.9) | 2 (1.6) |
| Infections (viral herpes) | 1 (0.5) | 1 (0.5) | 1 (0.5) | 0 |
| Infections (mycobacterial) | 1 (0.5) | 0 | 0 | 0 |
| Infections (skin structure) | 5 (2.7) | 15 (7.1) | 12 (5.6) | 4 (3.2) |
| Infections (staphylococcal) | 0 | 1 (0.5) | 4 (1.9) | 0 |
| Major adverse cardiovascular events (MACE) | 7 (3.8) | 5 (2.4) | 8 (3.8) | 0 |
| Malignant or unspecified tumours | 3 (1.6) | 1 (0.5) | 0 | 1 (0.8) |
| Malignant or unspecified tumours (except NMSC) | 3 (1.6) | 1 (0.5) | 0 | 1 (0.8) |
| Neutropenia | 0 | 1 (0.5) | 0 | 0 |
aPatients who were not taking medication at certain times during the study. Percentages are based on the number of patients from the EXS for each respective actual treatment cohort
AE adverse event, EXS exposed set, MACE major adverse cardiac events, N total number of patients, n number of patients, NMSC non-melanoma skin cancer